PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.

被引：1
|
作者：
Villagrasa, Patricia
Gonzalez, Xavier
Oliveira, Mafalda
Vazquez, Josep
De La Pena, Lorena
Llobet-Canela, Marta
Prat, Aleix
Ciruelos, Eva
机构：
[1] SOLTI Breast Canc Res Grp, Barcelona, Spain
[2] Quiron Dexeus Univ Hosp, Translat Res Unit, Dr Rosell Oncol Inst, Barcelona, Spain
[3] Vall dHebron Univ Hosp VHIO, Barcelona, Spain
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] Hosp Univ 12 Octubre, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps642
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS642
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer
    Cascetta, Krystal P.
    Poulikakos, Poulikos
    Shapiro, Charles
    Fasano, Julie
    Bhardwaj, Aarti
    Irie, Hanna
    Goel, Anupama
    Klein, Paula
    Adams, Sylvia
    Kalinsky, Kevin
    Vahdat, Linda
    Ru, Meng
    Tiersten, Amy
    CANCER RESEARCH, 2018, 78 (04)
  • [22] Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Meguro, Takashi
    Hatanaka, Kazuteru
    Uebayashi, Minoru
    Nakamura, Michio
    Okuda, Hiroyuki
    Iwanaga, Ichiro
    Kato, Takashi
    Nakano, Shintaro
    Sato, Atsushi
    Harada, Kazuaki
    Oba, Koji
    Sakata, Yuh
    Sakamoto, Naoya
    Komatsu, Yoshito
    ONCOLOGIST, 2022, 27 (05): : 340 - +
  • [23] A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer
    Yardley, Denise A.
    Daniel, Davey
    Stipanov, Michael
    Drosick, D. Randolph
    Mainwaring, Mark
    Peyton, James
    Shastry, Mythili
    Hainsworth, John D.
    CANCER INVESTIGATION, 2010, 28 (08) : 865 - 871
  • [24] Phase II Study of Neratinib and Trastuzumab plus -oral Vinorelbine in previously treated metastatic Her2 positive Breast Cancer
    Balic, M.
    Posch, F.
    Bartsch, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 106 - 106
  • [25] Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
    Saura, C.
    Modi, S.
    Krop, I.
    Park, Y. H.
    Kim, S. -B.
    Tamura, K.
    Iwata, H.
    Tsurutani, J.
    Sohn, J.
    Mathias, E.
    Liu, Y.
    Cathcart, J.
    Singh, J.
    Yamashita, T.
    ANNALS OF ONCOLOGY, 2024, 35 (03) : 302 - 307
  • [26] Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).
    Freixinos, V.
    Sanchez-Olle, G.
    De Mattos-Arruda, L.
    Di Cosimo, S.
    Saura, C.
    Gomez, P.
    Perez-Garcia, J. M.
    Cortes, J.
    Baselga, J.
    Bellet, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
    Papaldo, P
    Fabi, A
    Ferretti, G
    Mottolese, M
    Cianciulli, AM
    Di Cocco, B
    Pino, MS
    Carlini, P
    Di Cosimo, S
    Sacchi, I
    Sperduti, I
    Nardoni, C
    Cognetti, F
    ANNALS OF ONCOLOGY, 2006, 17 (04) : 630 - 636
  • [28] Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205.
    Kawamoto, Yasuyuki
    Meguro, Takashi
    Yuki, Satoshi
    Nakatsumi, Hiroshi
    Sasaki, Takahide
    Hatanaka, Kazuteru
    Uebayashi, Minoru
    Iwanaga, Ichiro
    Abe, Nobuhiko
    Nakamura, Michio
    Okuda, Hiroyuki
    Eto, Kazunori
    Oba, Ayane
    Abe, Masakazu
    Oba, Koji
    Satoh, Taroh
    Sakata, Yuh
    Sakamoto, Naoya
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [29] Trastuzumab-Emtansine versus Capecitabine plus Lapatinib in Patients with previously treated HER2-positive metastatic Breast Cancer
    Ruckhaeberle, Eugen
    ONKOLOGE, 2017, 23 (11): : 940 - 942
  • [30] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study
    F Carabantes-Ocón
    E Saez-Lara
    L Burgos-Garcia
    E Villar-Chamorro
    A Casaus-Hazañas
    S Luna
    C Martínez
    Breast Cancer Research, 9
12345